Monitoring High-Stakes Toxicities and Making Treatment Decisions

This program was supported by Jazz Pharmaceuticals, content independence maintained by Pharmacy Times.

In this portion of the conversation, Matthew Arango, PharmD, discusses how pharmacists approach monitoring for cardiotoxicity when patients receive HER2-directed therapies, beginning with the baseline cardiac assessments needed before treatment starts. He explains the key LVEF thresholds and red-flag changes that should prompt intervention or treatment modification. Arango also describes the clinical indicators that help pharmacists judge when the risks of continuing therapy may outweigh its potential benefits, ensuring patient safety remains at the forefront of decision-making.